Raymond James Financial Inc. Purchases Shares of 638,092 InflaRx (NASDAQ:IFRX)

Raymond James Financial Inc. acquired a new position in InflaRx (NASDAQ:IFRX) during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund acquired 638,092 shares of the company’s stock, valued at approximately $1,576,000. Raymond James Financial Inc. owned 1.08% of InflaRx as of its most recent filing with the Securities and Exchange Commission (SEC).

InflaRx Stock Performance

NASDAQ IFRX opened at $1.05 on Wednesday. InflaRx has a twelve month low of $1.01 and a twelve month high of $2.82. The stock has a market cap of $70.49 million, a PE ratio of -0.97 and a beta of 1.98. The firm has a 50-day simple moving average of $1.77 and a 200 day simple moving average of $1.89.

InflaRx (NASDAQ:IFRX) last announced its quarterly earnings data on Thursday, March 20th. The company reported ($0.09) EPS for the quarter, topping analysts’ consensus estimates of ($0.27) by $0.18. InflaRx had a negative return on equity of 65.98% and a negative net margin of 33,362.70%. Research analysts forecast that InflaRx will post -1.04 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

IFRX has been the subject of a number of research analyst reports. Guggenheim upped their price target on InflaRx from $7.00 to $10.00 and gave the stock a “buy” rating in a report on Wednesday, March 26th. HC Wainwright reiterated a “buy” rating and set a $8.00 target price on shares of InflaRx in a research note on Friday, March 21st.

About InflaRx

InflaRx N.V., a clinical-stage biopharmaceutical company, discovers and develops inhibitors using C5a technology in Germany and the United States. The company's C5a is an inflammatory mediator that is involved in the progression of a variety of autoimmune and other inflammatory diseases. Its lead product candidate is vilobelimab, a novel intravenously delivered first-in-class anti-C5a monoclonal antibody, which completed the Phase III clinical trial for the treatment of hidradenitis suppurativa, a rare and chronic debilitating systemic inflammatory skin disease; for the treatment of anti-neutrophil cytoplasm antibody associated vasculitis, a rare and life-threatening autoimmune disease that is in Phase II trial; to treat pyoderma gangraenosum, a chronic inflammatory skin disorder that is in Phase IIa exploratory study; and for the treatment of PD-1/PD-L1 inhibitor resistant/refractory locally advanced or metastatic cutaneous squamous cell carcinoma that is in Phase II clinical development stage.